| OBERMANNOVA, R., Regina DEMLOVÁ, I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA, Marie MLNAŘÍKOVÁ, Kateřina PILÁTOVÁ, Jiří NEVRLKA, Hana LEJDAROVÁ, B. WEINBERGEROVA, Z. CERMAKOVA, Dalibor VALÍK, Jiří MAYER, Igor KISS a Lenka ZDRAŽILOVÁ DUBSKÁ. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity. In Congress of the European Society for Medical Oncology ESMO 2021. 2021. ISSN 0923-7534. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2021.08.1556. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1807081,
author = {Obermannova, R. and Demlová, Regina and Selingerova, I. and Doubek, M. and Okrouhlicova, D. and Mlnaříková, Marie and Pilátová, Kateřina and Nevrlka, Jiří and Lejdarová, Hana and Weinbergerova, B. and Cermakova, Z. and Valík, Dalibor and Mayer, Jiří and Kiss, Igor and Zdražilová Dubská, Lenka},
booktitle = {Congress of the European Society for Medical Oncology ESMO 2021},
doi = {http://dx.doi.org/10.1016/j.annonc.2021.08.1556},
keywords = {SARS-CoV-2; clinical trial; vaccines; Pfizer-BioNTech; AstraZeneca; Johnson & Johnson; Modern; adverse events},
language = {eng},
note = {CoVigi},
title = {CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity},
url = {https://www.annalsofoncology.org/article/S0923-7534(21)03785-6/fulltext},
year = {2021}
}
TY - CONF
ID - 1807081
AU - Obermannova, R. - Demlová, Regina - Selingerova, I. - Doubek, M. - Okrouhlicova, D. - Mlnaříková, Marie - Pilátová, Kateřina - Nevrlka, Jiří - Lejdarová, Hana - Weinbergerova, B. - Cermakova, Z. - Valík, Dalibor - Mayer, Jiří - Kiss, Igor - Zdražilová Dubská, Lenka
PY - 2021
TI - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
N1 - CoVigi
KW - SARS-CoV-2
KW - clinical trial
KW - vaccines
KW - Pfizer-BioNTech
KW - AstraZeneca
KW - Johnson & Johnson
KW - Modern
KW - adverse events
UR - https://www.annalsofoncology.org/article/S0923-7534(21)03785-6/fulltext
N2 - SARS-CoV-2 infection may be a threat for those undergoing active anti-cancer therapy. We aim to study adverse events, efficacy, and immune response in Covid-19 vaccinated patients focusing on possibly interfering therapy.
ER -
OBERMANNOVA, R., Regina DEMLOVÁ, I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA, Marie MLNAŘÍKOVÁ, Kateřina PILÁTOVÁ, Jiří NEVRLKA, Hana LEJDAROVÁ, B. WEINBERGEROVA, Z. CERMAKOVA, Dalibor VALÍK, Jiří MAYER, Igor KISS a Lenka ZDRAŽILOVÁ DUBSKÁ. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity. In \textit{Congress of the European Society for Medical Oncology ESMO 2021}. 2021. ISSN~0923-7534. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2021.08.1556.
|
